Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2018; 24(21): 2311-2319
Published online Jun 7, 2018. doi: 10.3748/wjg.v24.i21.2311
Published online Jun 7, 2018. doi: 10.3748/wjg.v24.i21.2311
Intralesional steroid is beneficial in benign refractory esophageal strictures: A meta-analysis
László Szapáry, Benedek Tinusz, Katalin Márta, Lajos Szakó, Ágnes Meczker, Alexandra Mikó, Péter Hegyi, Bálint Erőss, Institute for Translational Medicine, Medical School, University of Pécs, Pécs 7624, Hungary
Nelli Farkas, Institute of Bioanalysis, Medical School, University of Pécs, Pécs 7624, Hungary
Roland Hágendorn, Judit Bajor, Áron Vincze, Department of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs 7624, Hungary
Zoltán Gyöngyi, Department of Public Health Medicine, Medical School, University of Pécs, Pécs 7624, Hungary
Dezső Csupor, Department of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Szeged 6720, Hungary
Author contributions: Szapáry L, Erőss B and Hegyi P designed the research and the study concept; Szapáry L and Tinusz B performed the data extraction; Farkas N analysed and interpreted the data; Szapáry L and Tinusz B performed the quality assessment; Szapáry L, Tinusz B, and Erőss B wrote the article; Hágendorn R, Bajor J, Vincze Á, Gyöngyi Z, Mikó A supervised the study; Márta K, Szakó L, Meczker Á, Csupor D, Hegyi P and Erőss B conducted a critical revision of the manuscript for important intellectual content; all of the co-authors granted final approval of the version of the article to be published.
Supported by the Project Grant (KH125678 to PH) and an Economic Development and Innovation Operative Program Grant (GINOP 2.3.2-15-2016-00048 to PH) from the National Research, Development and Innovation Office.
Conflict-of-interest statement: The authors deny any conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Bálint Erőss, MD, Assistant Professor, Doctor, Institute for Translational Medicine, Medical School, University of Pécs, Szigeti út 12, Pécs 7624, Hungary. eross.balint@pte.hu
Telephone: +36-72-536246 Fax: +36-72-536247
Received: March 14, 2018
Peer-review started: March 15, 2018
First decision: March 27, 2018
Revised: March 29, 2018
Accepted: April 23, 2018
Article in press: April 23, 2018
Published online: June 7, 2018
Processing time: 81 Days and 12.2 Hours
Peer-review started: March 15, 2018
First decision: March 27, 2018
Revised: March 29, 2018
Accepted: April 23, 2018
Article in press: April 23, 2018
Published online: June 7, 2018
Processing time: 81 Days and 12.2 Hours
Core Tip
Core tip: Benign refractory stricture can be a very challenging pathology, which requires regular endoscopic dilations. Results of this meta-analysis suggest that endoscopic intralesional steroid injection significantly decreases the frequency of the endoscopic dilations in benign refractory esophageal strictures. In addition, there are very few and mild complications reported in association with this method. We believe that the benefits of intralesional steroid in the treatment of benign refractory stricture overweigh its risks. However, further research would be essential on this treatment method, as there are no data concerning its efficacy and safety in different etiologies of refractory esophageal strictures.